Navigation Links
Omeros to Present at Oppenheimer 24th Annual Healthcare Conference

SEATTLE, Dec. 5, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference in New York City next week.  The presentation is scheduled for Wednesday, December 11, 2013 at 1:35 p.m. EST.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at  

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's lead drug product, OMS302 for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with commercial launch planned for 2014. Omeros' five other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omeros Reports Phase 3 OMS302 Clinical Data Presented at the Annual American Academy of Ophthalmology Meeting
2. Omeros Announces Positive OMS721 Data in Model of Age-Related Macular Degeneration
3. FDA Grants Orphan Drug Designation to Omeros OMS824 for Huntingtons Disease
4. Omeros Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference
5. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
6. Omeros Reports Additional Positive Results from OMS824 Program
7. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
8. Omeros to Present at the Stifel Healthcare Conference 2013
9. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
10. Omeros Corporation Reports Second Quarter 2013 Financial Results
11. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 30, 2015 , ... The Cyber Monday deal is a deep 40% or more ... time to get gifts for the skin care lover in your circle. Each Christmas, ... . This year, the 3 serums are staples: Collagen, Retinol and Hyaluronic Serums. , Stocking ...
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic Analog Distortion from ... designed specially for Final Cut Pro X. FCPX users can now ... modification controls. Destoying and creating chaotic distortion is now quick and simple, putting ...
(Date:11/28/2015)... ... November 28, 2015 , ... Trying to relax on a couch can actually ... conceived of this design due to personal experience with a bad back," he said. ... and convenience, as well as increases support. It also makes it easier to eat, ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... ... 27, 2015 , ... "When I was traveling, I was ... N.J. "Many people catch diseases simply from sitting on such dirty toilet seats. ... from germs." , He developed the patent-pending QUDRATECS to eliminate the need to ...
Breaking Medicine News(10 mins):